GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (FRA:722) » Definitions » EV-to-EBITDA

Antengene (FRA:722) EV-to-EBITDA : -3.28 (As of Apr. 27, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Antengene EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Antengene's enterprise value is €129.07 Mil. Antengene's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €-39.34 Mil. Therefore, Antengene's EV-to-EBITDA for today is -3.28.

The historical rank and industry rank for Antengene's EV-to-EBITDA or its related term are showing as below:

FRA:722' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.16   Med: 0.7   Max: 1.97
Current: -3.51

During the past 7 years, the highest EV-to-EBITDA of Antengene was 1.97. The lowest was -4.16. And the median was 0.70.

FRA:722's EV-to-EBITDA is ranked worse than
100% of 508 companies
in the Biotechnology industry
Industry Median: 7.41 vs FRA:722: -3.51

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-04-27), Antengene's stock price is €0.312. Antengene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.066. Therefore, Antengene's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Antengene EV-to-EBITDA Historical Data

The historical data trend for Antengene's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene EV-to-EBITDA Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial -2.04 -4.12 -1.91 -0.25 1.16

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.91 - -0.25 - -

Competitive Comparison of Antengene's EV-to-EBITDA

For the Biotechnology subindustry, Antengene's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antengene's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Antengene's EV-to-EBITDA falls into.


;
;

Antengene EV-to-EBITDA Calculation

Antengene's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=129.073/-39.341
=-3.28

Antengene's current Enterprise Value is €129.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Antengene's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €-39.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antengene  (FRA:722) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Antengene's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.312/-0.066
=At Loss

Antengene's share price for today is €0.312.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Antengene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.066.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Antengene EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Antengene's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Antengene Business Description

Traded in Other Exchanges
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.

Antengene Headlines

No Headlines